BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…
LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and…
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH). Strainsforpains, Inc. is redefining…
Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under…
- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics,…
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of…
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare technologies Inc. (NASDAQ: MRM) (“MEDIROM”), a health technology and holistic healthcare…
- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group…
--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by…
– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters…